Pacific Biosciences of California Inc (NASDAQ: PACB): Hunting Genuine Value In Market Debris

Currently, there are 267.74M common shares owned by the public and among those 251.64M shares have been available to trade.

The company’s stock has a 5-day price change of -0.82% and -64.77% over the past three months. PACB shares are trading -62.79% year to date (YTD), with the 12-month market performance down to -61.90% lower. It has a 12-month low price of $3.45 and touched a high of $14.55 over the same period. PACB has an average intraday trading volume of 8.72 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.12%, -32.50%, and -58.55% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Institutional ownership of Pacific Biosciences of California Inc (NASDAQ: PACB) shares accounts for 98.39% of the company’s 267.74M shares outstanding.

It has a market capitalization of $978.02M and a beta (3y monthly) value of 1.82. The earnings-per-share (ttm) stands at -$1.21. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.68% over the week and 9.03% over the month.

Analysts forecast that Pacific Biosciences of California Inc (PACB) will achieve an EPS of -$0.27 for the current quarter, -$0.26 for the next quarter and -$0.86 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.3 while analysts give the company a high EPS estimate of -$0.24. Comparatively, EPS for the current quarter was -$0.36 a year ago. Earnings per share for the fiscal year are expected to increase by 14.46%, and 17.10% over the next financial year. EPS should grow at an annualized rate of -1.00% over the next five years, compared to -9.76% over the past 5-year period.

Looking at the support for the PACB, a number of firms have released research notes about the stock. Stephens stated their Overweight rating for the stock in a research note on December 14, 2023, with the firm’s price target at $11. Wolfe Research was of a view on December 13, 2023 that the stock is Peer Perform, while UBS gave the stock Buy rating on November 17, 2023, issuing a price target of $13- $10. Cantor Fitzgerald on their part issued Overweight rating on October 31, 2023.

Most Popular

Related Posts